Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemoradiotherapy in unresectable stage III NSCLC
ChiCTR2200058342Phase 4Recruiting
- Sponsor
- Xiamen Humanity Hospital
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Xiamen Humanity Hospital. Primary endpoint: 1-year progression-free survival rate. Started Apr 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200058342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058342.